Corona Remedies IPO Allotment Status Today: GMP, Subscription & How to Check Allotment Online | PL Capital

Mumbai | December 11, 2025

The Corona Remedies IPO allotment is expected to be completed today after the pharma company’s ₹655.37 crore public issue closed with exceptional demand. Investors focus now shifts to the allotment status, subscription numbers and the upcoming listing. The stock is scheduled to debut on the BSE and NSE on December 15, 2025. The IPO witnessed an extraordinary 137.04 times subscription across investor categories, reflecting strong institutional and retail participation. Once the allotment is finalised, shares will be credited to demat accounts tomorrow, while refunds for non-allottees will also be processed on December 12.

How to Check Corona Remedies IPO Allotment Status Online

Investors can check their allotment status on three platforms — BSE, NSE, and the registrar Bigshare Services.
Each option requires basic details such as PAN, application number, or DP/Client ID.

Check Allotment Status on BSE

Step 1: Visit the BSE allotment page:
https://www.bseindia.com/investors/appli_check.aspx

Step 2: Select ‘Equity’

Step 3: Choose Corona Remedies Ltd

Step 4: Enter Application Number or PAN

Step 5: Complete the captcha

Step 6: Click ‘Search’ to view allotment status

Check Allotment Status on NSE

Step 1: Visit the NSE IPO verification page:
https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids

Step 2: Select ‘Equity & SME IPO Bid Details’

Step 3: Choose Corona Remedies

Step 4: Enter PAN and Application Number

Step 5: Click ‘Submit’ to check status

Check Allotment Status on Bigshare Services (Registrar)

Step 1: Visit the Bigshare portal:
https://bigshareonline.com

Step 2: Select Corona Remedies Ltd

Step 3: Choose search type — Application No., Beneficiary ID, or PAN

Step 4: Enter the details

Step 5: Fill captcha and click ‘Search’ to view your allotment

Corona Remedies IPO Subscription Status

The Corona Remedies IPO received one of the strongest responses of the year. By the final day, the issue had been subscribed 137.04 times, driven mainly by institutional and non-institutional participation. While retail investors subscribed 28.73 times, non-institutional investors bid 208.88 times, and the Qualified Institutional Buyer segment saw a remarkable 278.52 times subscription.

Corona Remedies IPO Key Details

Corona Remedies IPO was entirely an Offer for Sale worth ₹655.37 crore, with promoters and existing shareholders including Sepia Investments, Anchor Partners and Sage Investment Trust reducing their holdings. The price band for the issue was set at ₹1,008 to ₹1,062 per share and the lot size for retail investors was fixed at 14 shares.
As this was a pure OFS, the proceeds will go to the selling shareholders. The stock is scheduled to list on December 15, 2025.

About The Company

Corona Remedies, headquartered in Ahmedabad, develops and markets pharmaceutical formulations across women’s health, cardio-diabetes, urology, pain management and wellness. It manages a portfolio of 67 brands as of December 2024 and operates two R&D centres recognised by the Department of Scientific and Industrial Research. Corona Remedies also runs manufacturing units in Gujarat and Himachal Pradesh and is in the process of commissioning a hormone production facility expected to begin operations in FY27.
Company’s business model is supported by strong distribution capabilities and continued investment in product development.

Corona Remedies Financial Highlights

For FY25, Corona Remedies reported revenue of ₹1,196.4 crore, reflecting 17.9 percent growth over the previous year. EBITDA grew to ₹240 crore, an increase of 55.1 percent year-on-year, while profit after tax rose sharply to ₹149.4 crore, marking 65.1 percent growth. The improvement in profitability was supported by better margins and operational efficiencies.

Corona Remedies IPO GMP Today

The IPO’s grey market premium remains strong at ₹295, indicating a potential listing price near ₹1,357. This translates into an estimated 27.78 percent premium over the upper price band.
Note: GMP does not represent official data and is based on speculation.

Stay updated on IPO listings, market trends and investment insights with PL Capital !